What is the 52 Week High and Low of Concord Biotech Share Price?

The 52 week high and low prices of Concord Biotech share price is 1980 & 987. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Concord Biotech Share price

Q: How to buy Concord Biotech Share at Choice?

To buy Concord Biotech stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Concord Biotech, choose your preferred order type, and place the trade.

CONCORDBIO

Healthcare Large Cap

1259.8

12.80 (-1.01%)

NSE

BSE

Last updated on 8 Jul, 2026 | 15:40 IST

BUYSELL

Today's High

1319.00

Today's Low

1253.20

52 Week Low

987.00

52 Week High

1980.00

Concord Biotech share price chart

ChartIQ

TradingView

Concord Biotech Share Key Metrics

Volume

1.57 L

Market Cap

13179.55 CR

LTQ@LTP

1@1259.80

ATP

1284.96

Var Margin

20.73 %

Circuit Range

1018.1-1527.1

Delivery %

47.87 %

Value

20.17 CR

ASM/GSM

No

Market Lot

1

Summary

CONCORDBIO stock price is ₹1259.8 as of 9 Jul, 2026. The stock intraday movement has stayed between ₹1253.20 and ₹1319.00, while Concord Biotech share price 52 week high low is ₹987.00 & ₹1980.00.

In terms of trading activity, CONCORDBIO share price has recorded a volume of 1,57,006 shares. The Concord Biotech has a market cap of ₹104616204. The stock’s Average Traded Price (ATP) stands at ₹1284.96, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹1259.80.

The Concord Biotech upper circuit limit is ₹1527.10 & The Concord Biotech lower circuit limit is ₹1018.10, with a Value of ₹20.17 CR. The Delivery Percentage for the day is 47.87%.

Additionally, the share currently falls under the No framework, and trades with a market lot size of ₹1.

Concord Biotech Fundamentals

P/E Ratio

50.99

P/B Ratio

6.6

Div. Yield

0.59

Sector P/E

69.28

Sector P/B

3.2

Sec. Div. Yield

0.52

Concord Biotech Resistance and Support

Pivot 1274.07

Resistance

First Resistance

1292.14

Second Resistance

1311.67

Third Resistance

1329.74

Support

First Support

1254.54

Second Support

1236.47

Third Support

1216.94

Concord Biotech Shareholding Pattern

2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

44.08%

Mutual Fund

4.3%

Insurance

3.89%

Foreign Institutional Investors

7.79%

Domestic Institutional Investors

1.04%

Retail

38.9%

Others

0%

Total Promoters

MAR '26

44.08%

Concord Biotech Corporate Actions

Date	Agenda
2026-05-29	Audited Results & Final Dividend
2026-02-11	Quarterly Results
2025-11-13	Quarterly Results
2025-08-08	Quarterly Results
2025-05-29	Audited Results & Final Dividend
2025-02-13	Quarterly Results

Concord Biotech News

Concord Biotech Ltd - 543960 - Intimation Of Record Date And Book Closure Date

Concord Biotech has fixed July 24, 2026, as the Record Date for its final dividend for FY26. Shareholders as of this date will be eligible for the dividend, with payment by August 30, 2026, subject to AGM approval.

Jul 07 2026 17:30:40

Concord Biotech Ltd - 543960 - Business Responsibility and Sustainability Reporting (BRSR)

Concord Biotech filed its Business Responsibility and Sustainability Report for FY2025-26. The report provides a comprehensive overview of the company's environmental, social, and governance performance, policies, and commitments, ensuring transparency and compliance.

Jul 07 2026 16:26:46

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Concord Biotech announced its 41st Annual General Meeting (AGM) will be held on July 31, 2026, through Video Conferencing/Other Audio-Visual Means. Shareholders will vote on the appointment of Mrs. Ekta Gupta as a Director and other agenda items.

Jul 06 2026 14:41:56

Concord Biotech Ltd - 543960 - Completion Of Inspection By The Pharmacy And Poisons Board (PPB) From Kenya And The National Drug Authority (NDA) From Uganda At Unit-II Formulation Facility

Concord Biotech's Unit-II formulation facility successfully completed inspections by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. This achievement marks a significant milestone in its global growth journey.

Jun 25 2026 10:03:00

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Concord Biotech officials will be participating in a Non-Deal Roadshow (NDR) in Mumbai on June 24-25, 2026. The meetings, organized by Kotak Equities, will involve 1x1 and group interactions with institutional investors. Discussions will be based on publicly available information, and no UPSI will be shared.

Jun 19 2026 15:13:04

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Concord Biotech will conduct virtual meetings with analysts and institutional investors on June 17, 2026, starting 10:30 am. No unpublished price sensitive information will be discussed.

Jun 13 2026 11:12:03

Concord Biotech Ltd - 543960 - Completion Of ANVISA Inspection Conducted By The Brazilian Health Regulatory Agency At The Limbasi API Manufacturing Facility

Concord Biotech successfully completed an ANVISA inspection by the Brazilian Health Regulatory Agency at its Limbasi API manufacturing facility. This strengthens its global regulatory footprint and supports international expansion.

Jun 12 2026 13:30:23

Concord Biotech Ltd - 543960 - Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Tofacitinib Tablets, 5 Mg And 10 Mg

Concord Biotech secured USFDA approval for its Tofacitinib Tablets (5mg & 10mg), opening access to an estimated US$500 million market in the U.S. This approval enhances the company's product offerings and supports its long-term growth strategy.

Jun 10 2026 10:08:29

Name	Position
Sudhir Vaid	Chairman & Managing Director
Ankur Vaid	Joint Managing Director & CEO

Concord Biotech Similar Stocks

Jubilant Pharmova Ltd.

970.75

-8.05 (0.82%)

Dr. Agarwal's Health Care Ltd.

477.85

5.30 (1.12%)

Rainbow Children's Medicare Ltd.

1431.10

9.10 (0.64%)

Vijaya Diagnostic Centre Ltd.

1326.00

-13.40 (1.00%)

Viyash Scientific Ltd.

270.60

-8.30 (2.98%)

Alivus Life Sciences Ltd.

1130.10

-14.60 (1.28%)

Park Medi World Ltd.

273.90

-11.45 (4.01%)

CORONA Remedies Ltd.

1979.40

-9.40 (0.47%)

Metropolis Healthcare Ltd.

549.35

-16.80 (2.97%)

Concord Biotech FAQs

The Buying Price of Concord Biotech share is 1259.8 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Concord Biotech stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Concord Biotech, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Concord Biotech shares is 50.99. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Concord Biotech shares is 6.6. Useful to assess the stock's value relative to its book value.

To assess Concord Biotech’s valuation compare Sector P/E, P/B which are 69.28 & 3.2 with sector averages, along with growth rates and financial metrics.

The Market Cap of Concord Biotech is 13179.55 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Concord Biotech share price is 1980.00 & 987.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Concord Biotech belongs to the Healthcare sector.